EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibacterial Activity and Mode of Action of C4-AII, a Novel Peptide Derived from Human Complement C4A Protein

Yajie Li, Xuenan Fan, Ritian Jin, Duo Liang, Wuyin Weng, Zhongyang Ren, Shen Yang, Rong Lin

Antibiotics · 14.11.2026 · 15 (11) · 1139

DOI: 10.3390/antibiotics15111139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibiotics, online erschienen am 14.11.2026. Verfasst von Yajie Li und 7 weiteren Autor:innen. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The human nasal cavity produces antimicrobial peptides (AMPs) that contribute to protection against microbial pathogens, including Staphylococcus aureus. Most of these AMPs originate from endogenous proteins with or without known immune-related functions.

Methods

C4-AII was identified and selected from human nasal fluid by mass spectrometry, and its antibacterial activity, mechanism, and biocompatibility were characterized by broth microdilution MIC/MBC and time-kill assays, membrane permeability and DNA gel retardation assays, LO2 cell viability and hemolysis assays, and a glass-slide surface spray model.

Results

Here, a peptide derived from complement C4A, designated C4-AII, was identified in human nasal fluid and exhibited MIC/MBC values of 8/15.6 μg/mL against S. aureus and 16/32 μg/mL against methicillin-resistant Staphylococcus aureus. C4-AII completely eliminated S. aureus within 3 h and increased bacterial membrane permeability, resulting in protein and nucleic acid leakage. In vitro gel retardation assays further demonstrated the ability of C4-AII to interact with purified bacterial genomic DNA. C4-AII also exhibited low cytotoxicity toward LO2 cells and low hemolytic activity under the tested in vitro conditions. Furthermore, a surface spray model demonstrated concentration-dependent bactericidal activity against S. aureus under contact-based exposure conditions.

Conclusions

These findings identify C4-AII as a C4A-derived antibacterial peptide from human nasal fluid and support further investigation of human body fluids as a source of antimicrobial peptides.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, Y., Fan, X., Jin, R., Liang, D., Weng, W., Ren, Z., Yang, S., & Lin, R. (2026). Antibacterial Activity and Mode of Action of C4-AII, a Novel Peptide Derived from Human Complement C4A Protein. Antibiotics, 15(11), 1139. https://doi.org/10.3390/antibiotics15111139

Vancouver

Li Y, Fan X, Jin R, Liang D, Weng W, Ren Z, et al. Antibacterial Activity and Mode of Action of C4-AII, a Novel Peptide Derived from Human Complement C4A Protein. Antibiotics. 2026;15(11):1139. doi:10.3390/antibiotics15111139

BibTeX
@article{Li2026,
  author = {Li, Yajie and Fan, Xuenan and Jin, Ritian and Liang, Duo and Weng, Wuyin and Ren, Zhongyang and Yang, Shen and Lin, Rong},
  title = {Antibacterial Activity and Mode of Action of C4-AII, a Novel Peptide Derived from Human Complement C4A Protein},
  journal = {Antibiotics},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {1139},
  doi = {10.3390/antibiotics15111139}
}
Kostenlos starten →